US8158120B2ExpiredUtilityA1

Cardiac muscle repair or regeneration using bone marrow-derived stem cells

96
Assignee: PITTENGER MARK FPriority: Jul 14, 1997Filed: Mar 17, 2010Granted: Apr 17, 2012
Est. expiryJul 14, 2017(expired)· nominal 20-yr term from priority
A61P 9/00A61P 9/04A61P 9/10A61K 48/00C12N 2533/54A61K 35/12C12N 2500/99A61P 21/00C12N 2510/02C12N 5/0663C12N 2500/90A61K 2035/124A61K 35/28C12N 5/0657
96
PatentIndex Score
26
Cited by
76
References
10
Claims

Abstract

Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.

Claims

exact text as granted — not AI-modified
1. A method of improving left ventricular ejection fraction in a patient comprising the step of:
 administering to the patient adult allogeneic mesenchymal stem cells in an amount effective to improve ventricular ejection fraction. 
 
     
     
       2. The method of  claim 1 , wherein the stem cells are administered intravenously or intraarterially. 
     
     
       3. The method of  claim 1 , wherein the mesenchymal stem cells are administered in a pharmaceutically acceptable liquid carrier. 
     
     
       4. The method of  claim 3 , wherein the pharmaceutically acceptable carrier comprises an isotonic liquid. 
     
     
       5. The method of  claim 4 , wherein the isotonic liquid comprises phosphate buffer saline, physiological saline, culture medium, or 5% dextrose in water. 
     
     
       6. The method of  claim 4 , wherein the pharmaceutically acceptable carrier comprises phosphate buffer saline. 
     
     
       7. The method of  claim 1 , wherein the mesenchymal stem cells are administered in a suspension containing about 10×10 6  to about 40×10 6  mesenchymal stem cells per ml. 
     
     
       8. The method of  claim 7 , wherein the cell suspension is administered in an amount of about 20 μl to about 150 ml. 
     
     
       9. The method of  claim 7 , wherein the cell suspension is at least about 20 μl. 
     
     
       10. The method of  claim 7 , wherein the cell suspension is at least about 500 μl.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.